BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

468 related articles for article (PubMed ID: 6616449)

  • 1. Extraction of immunogenic and suppressogenic antigens from variants of B16 melanoma exhibiting low or high metastatic potentials.
    LeGrue SJ; Hearn DR
    Cancer Res; 1983 Nov; 43(11):5106-11. PubMed ID: 6616449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Suppression of B16 melanoma lung colonization by syngeneic monoclonal antibodies.
    Herd ZL
    Cancer Res; 1987 May; 47(10):2696-703. PubMed ID: 3552203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of tumor antigen correlated with metastatic potential of Lewis lung carcinoma and B16 melanoma clones in mice.
    Falcioni R; Kennel SJ; Giacomini P; Zupi G; Sacchi A
    Cancer Res; 1986 Nov; 46(11):5772-8. PubMed ID: 3756921
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Multiple antigens related to the major envelope glycoprotein of murine leukemia virus expressed on B16 melanoma cells as targets of host immune response.
    Stackpole CW; Demsey A
    Invasion Metastasis; 1984; 4(1):28-46. PubMed ID: 6329988
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differences in cytotoxic effects of activated murine peritoneal macrophages and J774 monocytic cells on metastatic variants of B16 melanoma.
    Miner KM; Klostergaard J; Granger GA; Nicolson GL
    J Natl Cancer Inst; 1983 Apr; 70(4):717-24. PubMed ID: 6339778
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of experimental metastasis and extracellular matrix degradation by butanol extracts from B16-F1 murine melanoma.
    Keren Z; Leland F; Nakajima M; LeGrue SJ
    Cancer Res; 1989 Jan; 49(2):295-300. PubMed ID: 2910449
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor cell and host properties affecting the implantation and survival of blood-borne metastatic variants of B16 melanoma.
    Fidler IJ; Nicolson GL
    Isr J Med Sci; 1978 Jan; 14(1):38-50. PubMed ID: 632082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mechanism of tumor cell resistance to lysis by syngeneic lymphocytes.
    Fidler IJ; Bucana C
    Cancer Res; 1977 Nov; 37(11):3945-56. PubMed ID: 908034
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of the immunomodulator LS 2616 on growth and metastasis of the murine B16-F10 melanoma.
    Kalland T
    Cancer Res; 1986 Jun; 46(6):3018-22. PubMed ID: 3486041
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of tunicamycin on B16 metastatic melanoma cell surface glycoproteins and blood-borne arrest and survival properties.
    Irimura T; Gonzalez R; Nicolson GL
    Cancer Res; 1981 Sep; 41(9 Pt 1):3411-8. PubMed ID: 7260906
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combined vaccination with major histocompatibility class I and interleukin 2 gene-transduced melanoma cells synergizes the cure of postsurgical established lung metastases.
    Porgador A; Tzehoval E; Vadai E; Feldman M; Eisenbach L
    Cancer Res; 1995 Nov; 55(21):4941-9. PubMed ID: 7585534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correlation of the production of plasminogen activator with tumor metastasis in B16 mouse melanoma cell lines.
    Wang BS; McLoughlin GA; Richie JP; Mannick JA
    Cancer Res; 1980 Feb; 40(2):288-92. PubMed ID: 7356511
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization in vivo and in vitro of tumor cells selected for resistance to syngeneic lymphocyte-mediated cytotoxicity.
    Fidler IJ; Gersten DM; Budmen MB
    Cancer Res; 1976 Sep; 36(9 pt.1):3160-5. PubMed ID: 975082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy of metastases with lymphocytes treated with exogenous RNA in mice bearing B16 melanoma.
    Watanabe MA; Almeida DO; Serrano SV; Sales VS; Soares FA; de Lucca FL
    Cell Mol Biol (Noisy-le-grand); 1997 May; 43(3):393-8. PubMed ID: 9193794
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serologically detectable MHC and tumor-associated antigens on B16 melanoma variants and humoral immunity in mice bearing these tumors.
    Baniyash M; Smorodinsky NI; Yaakubovicz M; Witz IP
    J Immunol; 1982 Sep; 129(3):1318-23. PubMed ID: 7108209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reduced tumorigenicity of B16-F10 mouse melanoma cells transfected with mycobacterial antigen 85A.
    Tarrant JP; Walsh MJ; Blanchard MC; Lee TD; Hoskin DW; Giacomantonio CA
    Int J Oncol; 2004 Dec; 25(6):1693-9. PubMed ID: 15547707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth inhibition of established B16-F10 lung metastases by sequential aerosol delivery of p53 gene and 9-nitrocamptothecin.
    Gautam A; Waldrep JC; Densmore CL; Koshkina N; Melton S; Roberts L; Gilbert B; Knight V
    Gene Ther; 2002 Mar; 9(5):353-7. PubMed ID: 11938455
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chemoimmunotherapy for melanoma with dacarbazine and 2,4-dinitrochlorobenzene elicits a specific T cell-dependent immune response.
    Wack C; Kirst A; Becker JC; Lutz WK; Bröcker EB; Fischer WH
    Cancer Immunol Immunother; 2002 Oct; 51(8):431-9. PubMed ID: 12202904
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between cellular procoagulant activity and metastatic capacity of B16 mouse melanoma variants.
    Gilbert LC; Gordon SG
    Cancer Res; 1983 Feb; 43(2):536-40. PubMed ID: 6848176
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differential extraction of tumor-specific transplantation antigen and embryonic antigen from simian virus 40- and adenovirus 7-induced sarcoma cells of hamsters with 1-butanol and 3 M potassium chloride.
    Coggin JH; Gillis LD; Payne WJ
    J Natl Cancer Inst; 1984 Apr; 72(4):853-62. PubMed ID: 6323810
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.